E M Gore1, C A Lawton, R C Ash, R J Lipchik. 1. Medical College of Wisconsin Affiliated Hospitals, Department of Radiation Oncology, Milwaukee 53226, USA.
Abstract
PURPOSE: This study was undertaken to evaluate long-term pulmonary function changes in patients undergoing bone marrow transplantation (BMT), to assess their clinical significance, and to identify factors influencing these changes. METHODS AND MATERIALS: Pulmonary function tests (PFT) were evaluated before and after BMT in 111 adult patients undergoing BMT between 1985 and 1991. Forced expiratory volume at 1 s (FEV1), forced vital capacity (FVC), diffusing capacity (DLCO), and total lung capacity (TLC) were evaluated. One hundred and three patients (92.8%) received total body irradiation (TBI) to a total dose of 14 Gy in nine equal fractions. The lung dose was restricted to < 6.5 Gy in 95% of patients with partial transmission lung shielding. Seventy-eight percent of patients had acute graft-versus-host disease (aGVHD), 69% chronic graft-vs.-host disease (cGVHD), and 63% posttransplant pulmonary infection. Effects of GVHD, TBI, radiation dose to the lungs, dose rate of TBI, posttransplant pulmonary infection, Busulfan use for conditioning, age, and history of smoking were evaluated for their influence on pulmonary function. RESULTS: Posttransplant FEV1, FVC, and TLC were lower than pretransplant values (p < 0.05) at 6 months and 1 year posttransplant with subsequent recovery. DLCO was significantly lower at all posttransplant intervals. FEV1 did not fall significantly in patients without acute or chronic GVHD and recovered earlier than in patients without posttransplant pulmonary infection. Recovery of FVC, TLC, and DLCO was also delayed in patients with acute and chronic GVHD and posttransplant pulmonary infection. Multiple regression analysis revealed an association between a higher radiation dose to the lungs, and decreased FVC at 2 years (p = 0.01). Progressive obstructive pulmonary disease was not observed. CONCLUSION: An initial decline in PFTs with subsequent recovery was observed. Factors associated with delayed recovery and incomplete recovery of PFTs were GVHD, posttransplant pulmonary infection, and higher radiation dose to the lungs. The conditioning regimen used at Medical College of Wisconsin, including relatively high TBI doses with partial transmission pulmonary shielding, appears to be well tolerated by the lungs in long-term survivors. No progressive decline in PFTs or symptomatic decline in pulmonary function was observed during the time interval studied.
PURPOSE: This study was undertaken to evaluate long-term pulmonary function changes in patients undergoing bone marrow transplantation (BMT), to assess their clinical significance, and to identify factors influencing these changes. METHODS AND MATERIALS: Pulmonary function tests (PFT) were evaluated before and after BMT in 111 adult patients undergoing BMT between 1985 and 1991. Forced expiratory volume at 1 s (FEV1), forced vital capacity (FVC), diffusing capacity (DLCO), and total lung capacity (TLC) were evaluated. One hundred and three patients (92.8%) received total body irradiation (TBI) to a total dose of 14 Gy in nine equal fractions. The lung dose was restricted to < 6.5 Gy in 95% of patients with partial transmission lung shielding. Seventy-eight percent of patients had acute graft-versus-host disease (aGVHD), 69% chronic graft-vs.-host disease (cGVHD), and 63% posttransplant pulmonary infection. Effects of GVHD, TBI, radiation dose to the lungs, dose rate of TBI, posttransplant pulmonary infection, Busulfan use for conditioning, age, and history of smoking were evaluated for their influence on pulmonary function. RESULTS: Posttransplant FEV1, FVC, and TLC were lower than pretransplant values (p < 0.05) at 6 months and 1 year posttransplant with subsequent recovery. DLCO was significantly lower at all posttransplant intervals. FEV1 did not fall significantly in patients without acute or chronic GVHD and recovered earlier than in patients without posttransplant pulmonary infection. Recovery of FVC, TLC, and DLCO was also delayed in patients with acute and chronic GVHD and posttransplant pulmonary infection. Multiple regression analysis revealed an association between a higher radiation dose to the lungs, and decreased FVC at 2 years (p = 0.01). Progressive obstructive pulmonary disease was not observed. CONCLUSION: An initial decline in PFTs with subsequent recovery was observed. Factors associated with delayed recovery and incomplete recovery of PFTs were GVHD, posttransplant pulmonary infection, and higher radiation dose to the lungs. The conditioning regimen used at Medical College of Wisconsin, including relatively high TBI doses with partial transmission pulmonary shielding, appears to be well tolerated by the lungs in long-term survivors. No progressive decline in PFTs or symptomatic decline in pulmonary function was observed during the time interval studied.
Authors: Eric P Cohen; Manpreet Bedi; Amy A Irving; Elizabeth Jacobs; Rade Tomic; John Klein; Colleen A Lawton; John E Moulder Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-19 Impact factor: 7.038
Authors: Jeanne Palmer; Kirsten Williams; Yoshihiro Inamoto; Xiaoyu Chai; Paul J Martin; Linus Santo Tomas; Corey Cutler; Daniel Weisdorf; Brenda F Kurland; Paul A Carpenter; Joseph Pidala; Steven Z Pavletic; William Wood; David Jacobsohn; Sally Arai; Mukta Arora; Madan Jagasia; Georgia B Vogelsang; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2013-12-04 Impact factor: 5.742
Authors: Alba Ramirez-Sarmiento; Mauricio Orozco-Levi; Eric C Walter; Margaret A Au; Jason W Chien Journal: Biol Blood Marrow Transplant Date: 2009-09-23 Impact factor: 5.742
Authors: Natasha A Jain; Priyanka A Pophali; Jeffrey K Klotz; Sawa Ito; Eleftheria Koklanaris; Kamna Chawla; Christopher S Hourigan; Nicole Gormley; Bipin N Savani; Austin John Barrett; Minoo Battiwalla Journal: Biol Blood Marrow Transplant Date: 2013-11-02 Impact factor: 5.742
Authors: Diana Ditz; Robert Rabanus; Christian Schulz; Daniel Wolff; Barbara Holler; Ernst Holler; Gerhard Carl Hildebrandt Journal: Croat Med J Date: 2016-02 Impact factor: 1.351